Ligand Pharmaceuticals Incorporated
A biopharmaceutical company that licenses drug technologies and collects royalties on medicines its partners develop and sell. Its best-known asset is Captisol, a sugar-based "cage" that wraps around hard-to-dissolve drugs to make them stable and deliverable. Founded in 1987 as Progenx, Inc., it was renamed Ligand Pharmaceuticals in 1989 after the biochemistry term for a molecule that binds to a receptor — a nod to its original focus on receptor biology.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Invesco Ltd. | 13GPassive | 6.1% | 1.22M | Aug 13, 2026 |
| Vanguard Portfolio Management | 13GPassive | 5.56% | 1.11M | May 1, 2026 |
| Vanguard Capital Management | 13GPassive | 5% | 997.6K | May 1, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| JANUS HENDERSON GROUP PLC | 13G/APassive | 5.3% | 1.04M | Nov 14, 2025 |
| BlackRock, Inc. | 13G/APassive | 14.5% | 2.84M | Oct 17, 2025 |